Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Bellmunt Molins, Joaquim, 1959-
- dc.contributor.author Valderrama, Begoña P.
- dc.contributor.author Puente, Javier
- dc.contributor.author Grande, Enrique
- dc.contributor.author Bolós, M. Victoria
- dc.contributor.author Lainez, Nuria
- dc.contributor.author Vázquez, Sergio
- dc.contributor.author Maroto, Pablo
- dc.contributor.author Climent, Miguel Ángel
- dc.contributor.author Garcia del Muro, Xavier
- dc.contributor.author Arranz, José Ángel
- dc.contributor.author Durán, Ignacio
- dc.date.accessioned 2022-09-02T06:30:47Z
- dc.date.available 2022-09-02T06:30:47Z
- dc.date.issued 2022
- dc.description.abstract Management of first-line advanced urothelial carcinoma (UC) has consisted during the past three decades in the administration of platinum-based chemotherapy followed by observation. Despite moderate to high response rates to first-line treatment, most patients will relapse shortly after and the outcomes with subsequent therapies are poor with 5-year overall survival rates of 5% in the pre-immunotherapy era. Nonetheless, recent therapeutic developments including the paradigm shift of first-line maintenance therapy with avelumab after response or stabilization on platinum-based chemotherapy, along with the incorporation of new drug classes in further lines of treatment such as antibody drug-conjugates and fibroblast growth factor receptor inhibitors have reshaped the field leading to better outcomes in this patient population. This article reviews the current state of the art with an overview on UC management, recent advances, and the upcoming strategies currently in development in advanced UC with an insight into the biology of this disease.
- dc.format.mimetype application/pdf
- dc.identifier.citation Bellmunt J, Valderrama BP, Puente J, Grande E, Bolós MV, Lainez N, Vázquez S, Maroto P, Climent MÁ, Garcia Del Muro X, Arranz JÁ, Durán I. Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management. Crit Rev Oncol Hematol. 2022 Jun;174:103683. DOI: 10.1016/j.critrevonc.2022.103683
- dc.identifier.doi http://dx.doi.org/10.1016/j.critrevonc.2022.103683
- dc.identifier.issn 1040-8428
- dc.identifier.uri http://hdl.handle.net/10230/53977
- dc.language.iso eng
- dc.publisher Elsevier
- dc.relation.ispartof Crit Rev Oncol Hematol. 2022 Jun;174:103683
- dc.rights © 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by- nc-nd/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.subject.keyword Antibody drug-conjugate (ADC)
- dc.subject.keyword Avelumab
- dc.subject.keyword Bladder cancer
- dc.subject.keyword Checkpoint inhibitors (CPIs)
- dc.subject.keyword Platinum-based chemotherapy
- dc.subject.keyword Switch maintenance
- dc.subject.keyword Urothelial carcinoma (UC)
- dc.title Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion